stoxline Quote Chart Rank Option Currency Glossary
  
AIM ImmunoTech Inc. (AIM)
0.0949  -0.023 (-19.37%)    04-04 10:10
Open: 0.112
High: 0.1144
Volume: 2,305,517
  
Pre. Close: 0.1177
Low: 0.0633
Market Cap: 7(M)
Technical analysis
2025-05-23 4:45:50 PM
Short term     
Mid term     
Targets 6-month :  0.27 1-year :  0.42
Resists First :  0.23 Second :  0.36
Pivot price 0.07
Supports First :  0.02 Second :  0.02
MAs MA(5) :  0.09 MA(20) :  0.06
MA(100) :  0.13 MA(250) :  0.24
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  84 D(3) :  90.8
RSI RSI(14): 58.4
52-week High :  0.46 Low :  0.02
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AIM ] has closed below upper band by 25.5%. Bollinger Bands are 36.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.11 - 0.11 0.11 - 0.11
Low: 0.09 - 0.09 0.09 - 0.09
Close: 0.1 - 0.1 0.1 - 0.1
Company Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Headline News

Thu, 08 May 2025
AIM ImmunoTech Announces the Presentation of Ampligen - GlobeNewswire

Thu, 08 May 2025
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists - Stock Titan

Mon, 07 Apr 2025
Aim ImmunoTech CEO Thomas K Equels buys $2,583 in common stock - Investing.com

Mon, 07 Apr 2025
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market - GlobeNewswire

Fri, 04 Apr 2025
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - GlobeNewswire

Fri, 04 Apr 2025
NYSE American Suspends AIM ImmunoTech Trading: Company Fighting Delisting Notice - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 57 (M)
Held by Insiders 4.794e+007 (%)
Held by Institutions 8.9 (%)
Shares Short 629 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.136e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -7 %
Return on Assets (ttm) 388 %
Return on Equity (ttm) -80.1 %
Qtrly Rev. Growth 201000 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -23 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.34
Stock Dividends
Dividend 0
Forward Dividend 520200
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android